TRT Aveed denied for missing prior authorization by Humana?

Humana's specific coverage criteria for trt aveed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Aveed

Humana requires prior authorization (PA) for Aveed (testosterone undecanoate long-acting injection) before they will cover it. This is a prospective utilization management requirement — Humana wants clinical documentation reviewed before the drug is dispensed or administered. The denial you received may reflect either a missing PA (none was submitted) or a PA that was submitted and rejected for insufficient documentation.

## Why This Is Appealable

If a PA was submitted and denied, you have full appeal rights. If no PA was submitted and a claim was filed, the path is to obtain PA going forward and appeal for a retroactive exception if you have already received the medication. Either way, the underlying question — whether Aveed is medically necessary for this patient — is the same, and it is answerable with the right documentation.

## Federal Appeal Framework

• PA denial appeal: File within 180 days of the denial. Humana must respond within 30 days (standard) or 72 hours if a delay would seriously jeopardize health (expedited).
• Concurrent/expedited review: For Aveed, which is administered in a healthcare setting under a REMS program, request expedited review if a delay would leave a scheduled dose missed.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeal, you have approximately 4 months to request binding external review by an independent organization.

## Documentation to Gather

1. Diagnosis confirmation — Chart documentation of hypogonadism diagnosis, including clinical presentation, relevant laboratory workup (the actual lab reports, not a summary), and symptom history. 2. Prior treatment history — A complete record of any prior testosterone formulations tried, with start/stop dates and reason for each transition or discontinuation. Humana's PA criteria for testosterone therapy typically require documentation of prior treatment. 3. Clinical severity — Prescriber chart notes documenting the impact of hypogonadism on the patient's function and health, and the clinical rationale for testosterone replacement therapy. 4. Reason Aveed specifically — The prescriber must document why Aveed's long-acting injectable formulation is chosen over formulary alternatives. Aveed is administered in a certified healthcare setting under REMS; if the clinical rationale involves in-office administration, adherence, or prior failure of other routes, that must be explicit in the chart and PA request. 5. Prescriber PA letter — Maps each of Humana's published PA criteria for testosterone therapy to the specific, documented clinical facts in the chart. Obtain Humana's current PA criteria from their provider portal or coverage policy before drafting this letter. 6. REMS certification — Documentation that the prescribing provider and administration site are certified under the Aveed REMS program.

## Criteria-Mapping Structure

| Humana PA Criterion | Supporting Chart Documentation | |---|---| | Confirmed hypogonadism diagnosis | [Lab report date + ordering provider + clinical note] | | Prior testosterone therapy | [Each agent, dates, outcome] | | Clinical severity/functional impact | [Chart note + prescriber assessment] | | Reason for Aveed vs. formulary alternatives | [Prescriber letter explanation] | | REMS compliance | [Certified prescriber + site documentation] |

Obtain Humana's current prior authorization criteria from humana.com or the provider portal before submitting — criteria change annually and your submission must address the version in effect on your denial date.